Breastfeeding behaviors and the innate immune system of human milk: Working together to protect infants against inflammation, HIV-1, and other infections

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Henrick, Bethany M ^a   Yao, Xiao Dan ^b   Nasser, Laila ^b   Roozrogousheh, Ava ^b   Rosenthal, Kenneth L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Breast milk; Breastfeeding behaviors; HIV 1; Human breast milk stem cells; Human milk oligosaccharides; Innate immune bioactive factors; Mother to child HIV transmission; Soluble toll like receptor 2

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 10; INTERLEUKIN 15; MICRORNA; MUCIN 1; OLIGOSACCHARIDE; TOLL LIKE RECEPTOR 2;

ANTIRETROVIRAL THERAPY; ATTITUDE TO BREAST FEEDING; BREAST MILK; CD8+ T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; REVIEW; VIRUS LOAD; VIRUS NEUTRALIZATION;

EID: 85036501338     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01631     Document Type: Review

References (184)

1. Grulee CG, Sanford HN, Schwartz H. Breast and artificially fed infants. JAMA (1935) 104:1986-88. doi:10.1001/jama.1935.02760220032011
2. Newburg DS. Innate immunity and human milk. J Nutr (2005) 135:1308-12
3. Newburg DS. Neonatal protection by an innate immune system of human milk consisting of oligosaccharides and glycans. J Anim Sci (2008) 87:26-34. doi:10.2527/jas.2008-1347
4. Newburg DS, Walker WA. Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res (2007) 61:2-8. doi:10.1203/01.pdr.0000250274.68571.18
5. Bryce J, Victora CG, Black RE. The unfinished agenda in child survival. Lancet (2013) 382:1049-59. doi:10.1016/S0140-6736(13)61753-5
6. United Nations. World Population Prospects The 2012 Revision. New York (2013). p. 1-118
7. Victora CG, Bahl R, Barros AJ, França GV, Horton S, Krasevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet (2016) 387:475-90. doi:10.1016/S0140-6736(15)01024-7
8. Rollins NC, Bhandari N, Hajeebhoy N, Horton S, Lutter CK, Martines JC, et al. Why invest, and what it will take to improve breastfeeding practices? Lancet (2016) 387:491-504. doi:10.1016/S0140-6736(15)01044-2
9. Sankar MJ, Sinha B, Chowdhury R, Bhandari N, Taneja S, Martines J, et al. Optimal breastfeeding practices and infant and child mortality: a systematic review and meta-analysis. Acta Paediatr (2015) 104:3-13. doi:10.1111/apa.13147
10. Victora CG, Barros AJD, Fuchs SC, Francisco A, Morris J, Hall AJ, et al. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Lancet (2000) 355:451-5. doi:10.1016/S0140-6736(00)82011-5
11. Ip S, Chung M, Raman G, Chew P, Magula N, DeVine D, et al. Breastfeeding and maternal and infant health outcomes in developed countries. Evid Rep Technol Assess (Full Rep) (2007) (153):1-186
12. Horta BL, Victora CG. Short-term Effects of Breastfeeding. A Systematic Review on the Benefits of Breastfeeding on Diarrhoea and Pneumonia Mortality. (2013)
13. Brandtzaeg P. Mucosal immunity: integration between mother and the breast-fed infant. Vaccine (2003) 21:3382-8. doi:10.1016/S0264-410X(03)00338-4
14. Brandtzaeg P. The gut as communicator between environment and host: immunological consequences. Eur J Pharmacol (2011) 668(Suppl 1):S16-32. doi:10.1016/j.ejphar.2011.07.006
15. Brandtzaeg P. The mucosal immune system and its integration with the mammary glands. J Pediatr (2010) 156:S8-15. doi:10.1016/j.jpeds.2009.11.014
16. Hanson LA, Korotkova M, Telemo ER. Breast-feeding, infant formulas, and the immune system. Ann Allergy Asthma Immunol (2003) 90:59-63. doi:10.1016/S1081-1206(10)61662-6
17. Kramer MS, Chalmers B, Hodnett ED, Sevkovskaya Z, Dzikovich I, Shapiro S, et al. Promotion of breastfeeding intervention trial (PROBIT): a randomized trial in the Republic of Belarus. JAMA (2001) 285:413-20. doi:10.1001/jama.285.4.413
18. Thapa S, Short RV, Potts M. Breast feeding, birth spacing and their effects on child survival. Nature (1988) 335:679-82. doi:10.1038/335679a0
19. Breastfeeding and HIV International Transmission Study Group, Coutsoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis (2004) 189:2154-66. doi:10.1086/420834
20. Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis (2006) 6:726-32. doi:10.1016/S1473-3099(06)70629-6
21. Kuhn L, Sinkala M, Kankasa C, Semrau K, Kasonde P, Scott N, et al. High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission. PLoS One (2007) 2:e1363. doi:10.1371/journal.pone.0001363
22. Coutsoudis A, Kuhn L, Pillay K, Coovadia HM. Exclusive breast-feeding and HIV transmission. AIDS (2002) 16:498-9. doi:10.1097/00002030-200202150-00028
23. IliffPJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS (2005) 19:699-708. doi:10.1097/01.aids.0000166093.16446.c9
24. Coovadia HM, Rollins NC, Bland RM, Little K, Coutsoudis A, Bennish ML, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet (2007) 369:1107-16. doi:10.1016/S0140-6736(07)60283-9
25. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Geneva: WHO (2011). p. 1-117
26. UNAIDS. Report on the Global AIDS Epidemic. (2012). p. 1-110. Available from: http://www.unaids.org/sites/default/files/media_asset/20121120_UNAIDS_Global_Report_2012_with_annexes_en_1.pdf
27. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun T-W, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med (2013) 369:1828-35. doi:10.1056/NEJMoa1302976
28. Schramm DB, Kuhn L, Gray GE, Tiemessen CT. In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers. J Acquir Immune Defic Syndr (2006) 42:545-53. doi:10.1097/01.qai.0000225009.30698.ce
29. WHO Organization. HIV and Infant Feeding. (2010). p. 1-58. Available from: http://whqlibdoc.who.int/publications/2010/9789241599535_eng.pdf
30. World Health Organization. Global HIV/AIDS Response. World Health Organization Progress Report 2011. Geneva: WHO (2011). p. 1-233
31. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, et al. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol (2006) 13:1111-8. doi:10.1128/CDLI.00426-05
32. Lyimo MA, Howell AL, Balandya E, Eszterhas SK, Connor RI. Innate factors in human breast milk inhibit cell-free HIV-1 but not cell-associated HIV-1 infection of CD4+ cells. J Acquir Immune Defic Syndr (2009) 51:117-24. doi:10.1097/QAI.0b013e3181a3908d
33. Kourtis AP, Wiener J, Kayira D, Chasela C, Ellington SR, Hyde L, et al. Health outcomes of HIV-exposed uninfected African infants. AIDS (2013) 27:749-59. doi:10.1097/QAD.0b013e32835ca29f
34. Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: pathogenesis, mechanisms and pathways. Clin Perinatol (2010) 37:721-37, vii. doi:10.1016/j.clp.2010.08.004
35. Van de Perre P, Rubbo P-A, Viljoen J, Nagot N, Tylleskär T, Lepage P, et al. HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV-1. Sci Transl Med (2012) 4:143sr3. doi:10.1126/scitranslmed.3003327
36. Vorbach C, Capecchi MR, Penninger JM. Evolution of the mammary gland from the innate immune system? Bioessays (2006) 28:606-16. doi:10.1002/bies.20423
37. Molinari CE, Casadio YS, Hartmann BT, Livk A, Bringans S, Arthur PG, et al. Proteome mapping of human skim milk proteins in term and preterm milk. J Proteome Res (2012) 11:1696-714. doi:10.1021/pr2008797
38. Aldrovandi GM, Kuhn L. What infants and breasts can teach us about natural protection from HIV infection. J Infect Dis (2010) 202(Suppl 3):S366-70. doi:10.1086/655972
39. Kuhn L, Trabattoni D, Kankasa C, Sinkala M, Lissoni F, Ghosh M, et al. HIV-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. J Pediatr (2006) 149:611-6. doi:10.1016/j.jpeds.2006.06.017
40. Hocini H, Belec L, Iscaki S, Garin B, Pillot J, Becquart P, et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses (1997) 13:1179-85. doi:10.1089/aid.1997.13.1179
41. Saeland E, de Jong MAWP, Nabatov AA, Kalay H, Geijtenbeek TBH, van Kooyk Y. MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. Mol Immunol (2009) 46:2309-16. doi:10.1016/j.molimm.2009.03.025
42. Groot F, Geijtenbeek TBH, Sanders RW, Baldwin CE, Sanchez-Hernandez M, Floris R, et al. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J Virol (2005) 79:3009-15. doi:10.1128/JVI.79.5.3009-3015.2005
43. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest (1995) 96:456-64. doi:10.1172/JCI118056
44. Henrick BM, Nag K, Yao X-D, Drannik AG, Aldrovandi GM, Rosenthal KL. Milk matters: soluble toll-like receptor 2 (sTLR2) in breast milk significantly inhibits HIV-1 infection and inflammation. PLoS One (2012) 7:e40138. doi:10.1371/journal.pone.0040138.t001
45. Semba RD, Miotti PG, Lan Y, Chiphangwi JD, Hoover DR, Dallabetta GA, et al. Maternal serum lactoferrin and vertical transmission of HIV. AIDS (1998) 12:331-2
46. van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK. Antiviral activities of lactoferrin. Antiviral Res (2001) 52:225-39. doi:10.1016/S0166-3542(01)00195-4
47. Bernt KM, Walker WA. Human milk as a carrier of biochemical messages. Acta Paediatr Scand (1999) 88:27-41. doi:10.1111/j.1651-2227.1999.tb01298.x
48. Gomez HF, Ochoa TJ, Carlin LG, Cleary TG. Human lactoferrin impairs virulence of Shigella flexneri. J Infect Dis (2003) 187:87-95. doi:10.1086/345875
49. Farquhar C, VanCott TC, Mbori-Ngacha DA, Horani L, Bosire RK, Kreiss JK, et al. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis (2002) 186:1173-6. doi:10.1086/343805
50. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood (1997) 90:1141-9
51. Fouda GG, Jaeger FH, Amos JD, Ho C, Kunz EL, Anasti K, et al. Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. Proc Natl Acad Sci U S A (2013) 110:18220-5. doi:10.1073/pnas.1307336110
52. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal (2009) 3:287-310. doi:10.1007/s12079-009-0075-1
53. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett (2006) 244:143-63. doi:10.1016/j.canlet.2006.02.017
54. Mansour RG, Stamper L, Jaeger F, McGuire E, Fouda G, Amos J, et al. The presence and anti-HIV-1 function of tenascin C in breast milk and genital fluids. PLoS One (2016) 11:e0155261. doi:10.1371/journal.pone.0155261
55. Henrick BM, Yao X-D, Drannik AG, Abimiku A, Rosenthal KL; INFANT Study Team. Soluble toll-like receptor 2 is significantly elevated in HIV-1 infected breast milk and inhibits HIV-1 induced cellular activation, inflammation and infection. AIDS (2014) 28:2023-32. doi:10.1097/QAD.0000000000000381
56. Raby A-C, Le Bouder E, Colmont C, Davies J, Richards P, Coles B, et al. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol (2009) 183:506-17. doi:10.4049/jimmunol.0802909
57. Henrick BM, Yao X-D, Taha AY, German JB, Rosenthal KL. Insights into soluble toll-like receptor 2 as a downregulator of virally induced inflammation. Front Immunol (2016) 7:157-9. doi:10.3389/fimmu.2016.00291
58. Drannik AG, Nag K, Yao X-D, Henrick BM, Jain S, Ball TB, et al. Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells. J Virol (2012) 86:4599-610. doi:10.1128/JVI.06561-11
59. Drannik AG, Henrick BM, Rosenthal KL. War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem Soc Trans (2011) 39:1427-32. doi:10.1042/BST0391427
60. Drannik AG, Nag K, Yao X-D, Henrick BM, Ball TB, Plummer FA, et al. Anti-HIV-1 activity of elafin depends on its nuclear localization and altered innate immune activation in female genital epithelial cells. PLoS One (2012) 7:e52738. doi:10.1371/journal.pone.0052738.g006
61. Drannik AG, Nag K, Yao X-D, Henrick BM, Sallenave J-M, Rosenthal KL. Trappin-2/elafin modulate innate immune responses of human endometrial epithelial cells to PolyI:C. PLoS One (2012) 7:e35866. doi:10.1371/journal.pone.0035866.g008
62. Pfaender S, Heyden J, Friesland M, Ciesek S, Ejaz A, Steinmann J, et al. Inactivation of hepatitis C virus infectivity by human breast milk. J Infect Dis (2013) 208:1943-52. doi:10.1093/infdis/jit519
63. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667-73. doi:10.1038/381667a0
64. Bosire R, Guthrie BL, Lohman-Payne B, Mabuka J, Majiwa M, Wariua G, et al. Longitudinal comparison of chemokines in breastmilk early postpartum among HIV-1-infected and uninfected Kenyan women. Breastfeed Med (2007) 2:129-38. doi:10.1089/bfm.2007.0009
65. Walter J, Ghosh MK, Kuhn L, Semrau K, Sinkala M, Kankasa C, et al. High concentrations of interleukin 15 in breast milk are associated with protection against postnatal HIV transmission. J Infect Dis (2009) 200:1498-502. doi:10.1086/644603
66. Evans C, Humphrey JH, Ntozini R, Prendergast AJ. HIV-exposed uninfected infants in Zimbabwe: insights into health outcomes in the pre-antiretroviral therapy era. Front Immunol (2016) 7:190. doi:10.3389/fimmu.2016.00190
67. ásbjörnsdóttir KH, Slyker JA, Weiss NS, Mbori-Ngacha D, Maleche-Obimbo E, Wamalwa D, et al. Breastfeeding is associated with decreased pneumonia incidence among HIV-exposed, uninfected Kenyan infants. AIDS (2013) 27:2809-15. doi:10.1097/01.aids.0000432540.59786.6d
68. Bork KA, Cournil A, Read JS, Newell ML, Cames C, Meda N, et al. Morbidity in relation to feeding mode in African HIV-exposed, uninfected infants during the first 6 mo of life: the Kesho Bora study. Am J Clin Nutr (2014) 100:1559-68. doi:10.3945/ajcn.113.082149
69. Coppa GV, Gabrielli O, Pierani P, Catassi C, Carlucci A, Giorgi PL. Changes in carbohydrate composition in human milk over 4 months of lactation. Pediatrics (1993) 91:637-41
70. Kunz C, RudloffS, Baier W, Klein N, Strobel S. Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu Rev Nutr (2000) 20:699-722. doi:10.1146/annurev.nutr.20.1.699
71. Niñonuevo MR, Park Y, Yin H, Zhang J, Ward RE, Clowers BH, et al. A strategy for annotating the human milk glycome. J Agric Food Chem (2006) 54:7471-80. doi:10.1021/jf0615810
72. Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr (2005) 25:37-58. doi:10.1146/annurev.nutr.25.050304.092553
73. Newburg DS. Glycobiology of human milk. Biochemistry (Mosc) (2013) 78:771-85. doi:10.1134/S0006297913070092
74. He Y, Liu S, Kling DE, Leone S, Lawlor NT, Huang Y, et al. The human milk oligosaccharide 2'-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation. Gut (2016) 65:33-46. doi:10.1136/gutjnl-2014-307544
75. Bode L. Recent advances on structure, metabolism, and function of human milk oligosaccharides. J Nutr (2006) 136:2127-30
76. Newburg DS. Oligosaccharides in human milk and bacterial colonization. J Pediatr Gastroenterol Nutr (2000) 30(Suppl 2):S8-17. doi:10.1097/00005176-200000002-00003
77. German JB, Freeman SL, Lebrilla CB, Mills DA. Human milk oligosaccharides: evolution, structures and bioselectivity as substrates for intestinal bacteria. Nestle Nutr Workshop Ser Pediatr Program (2008) 62:205-18; discussion 218-22. doi:10.1159/000146322
78. Smilowitz JT, Lebrilla CB, Mills DA, German JB, Freeman SL. Breast milk oligosaccharides: structure-function relationships in the neonate. Annu Rev Nutr (2014) 34:143-69. doi:10.1146/annurev-nutr-071813-105721
79. Cilieborg MS, Sangild PT, Jensen ML, Østergaard MV, Christensen L, Rasmussen SO, et al. a1,2-fucosyllactose does not improve intestinal function or prevent Escherichia coli F18 diarrhea in newborn pigs. J Pediatr Gastroenterol Nutr (2017) 64:310-8. doi:10.1097/MPG.0000000000001276
80. Simon PM, Goode PL, Mobasseri A, Zopf D. Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides. Infect Immun (1997) 65:750-7
81. Gustafsson A, Hultberg A, Sjöström R, Kacskovics I, Breimer ME, Borén T, et al. Carbohydrate-dependent inhibition of Helicobacter pylori colonization using porcine milk. Glycobiology (2006) 16:1-10. doi:10.1093/glycob/cwj031
82. Ruiz-Palacios GM, Cervantes LE, Ramos P, Chavez-Munguia B, Newburg DS. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem (2003) 278:14112-20. doi:10.1074/jbc. M207744200
83. Morrow AL, Ruiz-Palacios GM, Altaye M, Jiang X, Guerrero ML, Meinzen-Derr JK, et al. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr (2004) 145:297-303. doi:10.1016/j.jpeds.2004.04.054
84. Weichert S, Koromyslova A, Singh BK, Hansman S, Jennewein S, Schroten H, et al. Structural basis for norovirus inhibition by human milk oligosaccharides. J Virol (2016) 90:4843-8. doi:10.1128/JVI.03223-15
85. Naarding MA, Ludwig IS, Groot F, Berkhout B, Geijtenbeek TBH, Pollakis G, et al. Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 115:3256-64. doi:10.1172/JCI25105
86. van Liempt E, Bank CMC, Mehta P, Garciá-Vallejo JJ, Kawar ZS, Geyer R, et al. Specificity of DC-SIGN for mannose-and fucose-containing glycans. FEBS Lett (2006) 580:6123-31. doi:10.1016/j.febslet.2006.10.009
87. Hong P, Niñonuevo MR, Lee B, Lebrilla C, Bode L. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br J Nutr (2009) 101:482-6. doi:10.1017/S0007114508025804
88. Bode L, Kuhn L, Kim H-Y, Hsiao L, Nissan C, Sinkala M, et al. Human milk oligosaccharide concentration and risk of postnatal transmission of HIV through breastfeeding. Am J Clin Nutr (2012) 96:831-9. doi:10.3945/ajcn.112.039503
89. Angeloni S, Ridet JL, Kusy N, Gao H, Crevoisier F, Guinchard S, et al. Glycoprofiling with micro-arrays of glycoconjugates and lectins. Glycobiology (2005) 15:31-41. doi:10.1093/glycob/cwh143
90. Kuntz S, RudloffS, Kunz C. Oligosaccharides from human milk influence growth-related characteristics of intestinally transformed and non-transformed intestinal cells. Br J Nutr (2008) 99:462-71. doi:10.1017/S0007114507824068
91. Bode L. The functional biology of human milk oligosaccharides. Early Hum Dev (2015) 91:619-22. doi:10.1016/j.earlhumdev.2015.09.001
92. Bienenstock J, Buck RH, Linke H, Forsythe P, Stanisz AM, Kunze WA. Fucosylated but not sialylated milk oligosaccharides diminish colon motor contractions. PLoS One (2013) 8:e76236. doi:10.1371/journal.pone.0076236
93. Eiwegger T, Stahl B, Schmitt J, Boehm G, Gerstmayr M, Pichler J, et al. Human milk-derived oligosaccharides and plant-derived oligosaccharides stimulate cytokine production of cord blood T-cells in vitro. Pediatr Res (2004) 56:536-40
94. Eiwegger T, Stahl B, Haidl P, Schmitt J, Boehm G, Dehlink E, et al. Prebiotic oligosaccharides: in vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties. Pediatr Allergy Immunol (2010) 21:1179-88. doi:10.1111/j.1399-3038.2010.01062.x
95. Castillo-Courtade L, Han S, Lee S, Mian FM, Buck R, Forsythe P. Attenuation of food allergy symptoms following treatment with human milk oligosaccharides in a mouse model. Allergy (2015) 70:1091-102. doi:10.1111/all.12650
96. Gyorgy P, Norris RF, Rose CS. Bifidus factor. I. A variant of Lactobacillus bifidus requiring a special growth factor. Arch Biochem Biophys (1954) 48:193-201. doi:10.1016/0003-9861(54)90323-9
97. Marcobal A, Barboza M, Froehlich JW, Block DE, German JB, Lebrilla CB, et al. Consumption of human milk oligosaccharides by gut-related microbes. J Agric Food Chem (2010) 58:5334-40. doi:10.1021/jf9044205
98. LoCascio RG, Desai P, Sela DA, Weimer B, Mills DA. Broad conservation of milk utilization genes in Bifidobacterium longum subsp. infantis as revealed by comparative genomic hybridization. Appl Environ Microbiol (2010) 76:7373-81. doi:10.1128/AEM.00675-10
99. Frese SA, Hutton AA, Contreras LN, Shaw CA, Palumbo MC, Casaburi G, et al. Persistence of supplemented bifidobacterium longum subsp. infantis EVC001 in breastfed infants. mSphere (2017) 2:e00501-17. doi:10.1128/mSphere.00501-17
100. Goldman AS. The immune system of human milk: antimicrobial, antiinflammatory and immunomodulating properties. Pediatr Infect Dis J (1993) 12:664-71. doi:10.1097/00006454-199308000-00008
101. Labbok MH, Clark D, Goldman AS. Breastfeeding: maintaining an irreplaceable immunological resource. Nat Rev Immunol (2004) 4:565-72. doi:10.1038/nri1393
102. Liu B, Newburg DS. Human milk glycoproteins protect infants against human pathogens. Breastfeed Med (2013) 8:354-62. doi:10.1089/bfm.2013.0016
103. Satomi M, Shimizu M, Shinya E, Watari E, Owaki A, Hidaka C, et al. Transmission of macrophage-tropic HIV-1 by breast-milk macrophages via DC-SIGN. J Infect Dis (2005) 191:174-81. doi:10.1086/426829
104. Hughes A, Brock JH, Parrott DM, Cockburn F. The interaction of infant formula with macrophages: effect on phagocytic activity, relationship to expression of class II MHC antigen and survival of orally administered macrophages in the neonatal gut. Immunology (1988) 64:213-8
105. Michie CA, Tantscher E, Schall T, Rot A. Physiological secretion of chemokines in human breast milk. Eur Cytokine Netw (1998) 9:123-9
106. Goldman AS. Human milk, leukocytes, and immunity. J Pediatr (1977) 90:167-8. doi:10.1016/S0022-3476(77)80805-6
107. Jain N, Mathur NB, Sharma VK, Dwarkadas AM. Cellular composition including lymphocyte subsets in preterm and full term human colostrum and milk. Acta Paediatr Scand (1991) 80:395-9. doi:10.1111/j.1651-2227.1991.tb11872.x
108. Hassiotou F, Geddes DT, Hartmann PE. Cells in human milk: state of the science. J Hum Lact (2013) 29:171-82. doi:10.1177/0890334413477242
109. Dahlstrand J, Zimmerman LB, McKay RD, Lendahl U. Characterization of the human nestin gene reveals a close evolutionary relationship to neurofilaments. J Cell Sci (1992) 103(Pt 2):589-97
110. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell (1990) 60:585-95. doi:10.1016/0092-8674(90)90662-X
111. Kabos P, Ehtesham M, Kabosova A, Black KL, Yu JS. Generation of neural progenitor cells from whole adult bone marrow. Exp Neurol (2002) 178:288-93. doi:10.1006/exnr.2002.8039
112. Cregan MD, Fan Y, Appelbee A, Brown ML, Klopcic B, Koppen J, et al. Identification of nestin-positive putative mammary stem cells in human breastmilk. Cell Tissue Res (2007) 329:129-36. doi:10.1007/s00441-007-0390-x
113. Hassiotou F, Beltran A, Chetwynd E, Stuebe AM, Twigger A-J, Metzger P, et al. Breastmilk is a novel source of stem cells with multilineage differentiation potential. Stem Cells (2012) 30:2164-74. doi:10.1002/stem.1188
114. Patki S, Kadam S, Chandra V, Bhonde R. Human breast milk is a rich source of multipotent mesenchymal stem cells. Hum Cell (2010) 23:35-40. doi:10.1111/j.1749-0774.2010.00083.x
115. Twigger AJ, Hodgetts S, Filgueira L, Hartmann PE, Hassiotou F. From breast milk to brains: the potential of stem cells in human milk. J Hum Lact (2013) 29:136-9. doi:10.1177/0890334413475528
116. Hassiotou F, Hartmann PE. At the dawn of a new discovery: the potential of breast milk stem cells. Adv Nutr (2014) 5:770-8. doi:10.3945/an.114.006924
117. Dutta P, Burlingham WJ. Stem cell microchimerism and tolerance to non-inherited maternal antigens. Chimerism (2010) 1:2-10. doi:10.4161/chim.1.1.12667
118. Rousseau CM, Nduati RW, Richardson BA, John-Stewart GC, Mbori-Ngacha DA, Kreiss JK, et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis (2004) 190:1880-8. doi:10.1086/425076
119. Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, Mbori-Ngacha DA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis (2003) 187:741-7. doi:10.1086/374273
120. Habte HH, de Beer C, Lotz ZE, Tyler MG, Schoeman L, Kahn D, et al. The inhibition of the human immunodeficiency virus type 1 activity by crude and purified human pregnancy plug mucus and mucins in an inhibition assay. Virol J (2008) 5:59. doi:10.1186/1743-422X-5-59
121. Habte HH, de Beer C, Lotz ZE, Tyler MG, Kahn D, Mall AS. Inhibition of human immunodeficiency virus type 1 activity by purified human breast milk mucin (MUC1) in an inhibition assay. Neonatology (2008) 93:162-70. doi:10.1159/000108414
122. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med (2004) 200:1337-46. doi:10.1084/jem.20041115
123. Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, Hershow RC, et al. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol (2007) 14:1102-7. doi:10.1128/CVI.00386-06
124. Yamaguchi K, Sugiyama T, Takizawa M, Yamamoto N, Honda M, Natori M. Viability of infectious viral particles of HIV and BMCs in breast milk. J Clin Virol (2007) 39:222-5. doi:10.1016/j.jcv.2007.04.011
125. Groot F, Welsch S, Sattentau QJ. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood (2008) 111:4660-3. doi:10.1182/blood-2007-12-130070
126. Chen P, Hübner W, Spinelli MA, Chen BK. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol (2007) 81:12582-95. doi:10.1128/JVI.00381-07
127. Kilewo C, Karlsson K, Massawe A, Lyamuya E, Swai A, Mhalu F, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr (2008) 48:315-23. doi:10.1097/QAI.0b013e31816e395c
128. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med (2010) 362:2282-94. doi:10.1056/NEJMoa0907736
129. Kantarci S, Koulinska IN, Aboud S, Fawzi WW, Villamor E. Subclinical mastitis, cell-associated HIV-1 shedding in breast milk, and breast-feeding transmission of HIV-1. J Acquir Immune Defic Syndr (2007) 46:651-4. doi:10.1097/QAI.0b013e31815b2db2
130. Koulinska IN, Villamor E, Chaplin B, Msamanga G, Fawzi W, Renjifo B, et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr (2006) 41:93-9. doi:10.1097/01.qai.0000179424.19413.24
131. Ndirangu J, Viljoen J, Bland RM, Danaviah S, Thorne C, Van de Perre P, et al. Cell-free (RNA) and cell-associated (DNA) HIV-1 and postnatal transmission through breastfeeding. PLoS One (2012) 7:e51493. doi:10.1371/journal.pone.0051493
132. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science (1992) 255:1134-7. doi:10.1126/science.1546316
133. Gantt S, Carlsson J, Heath L, Bull ME, Shetty AK, Mutsvangwa J, et al. Genetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis. J Virol (2010) 84:10812-9. doi:10.1128/JVI.00543-10
134. Salazar-Gonzalez JF, Salazar MG, Learn GH, Fouda GG, Kang HH, Mahlokozera T, et al. Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J Virol (2011) 85:2751-63. doi:10.1128/JVI.02316-10
135. Mabuka J, Goo L, Omenda MM, Nduati R, Overbaugh J. HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype. AIDS (2013) 27:1535-44. doi:10.1097/QAD.0b013e32835faba5
136. Henderson GJ, Hoffman NG, Ping LH, Fiscus SA, Hoffman IF, Kitrinos KM, et al. HIV-1 populations in blood and breast milk are similar. Virology (2004) 330:295-303. doi:10.1016/j.virol.2004.09.004
137. Dorosko SM, Connor RI. Primary human mammary epithelial cells endocytose HIV-1 and facilitate viral infection of CD4+ T lymphocytes. J Virol (2010) 84:10533-42. doi:10.1128/JVI.01263-10
138. Toniolo A, Serra C, Conaldi PG, Basolo F, Falcone V, Dolei A. Productive HIV-1 infection of normal human mammary epithelial cells. AIDS (1995) 9:859-66. doi:10.1097/00002030-199508000-00005
139. Lohman-Payne B, Slyker JA, Moore S, Maleche-Obimbo E, Wamalwa DC, Richardson BA, et al. Breast milk cellular HIV-specific interferon γ responses are associated with protection from peripartum HIV transmission. AIDS (2012) 26:2007-16. doi:10.1097/QAD.0b013e328359b7e0
140. Petitjean G, Becquart P, Tuaillon E, Tabaa Al Y, Valea D, Huguet M-F, et al. Isolation and characterization of HIV-1-infected resting CD4+ T lymphocytes in breast milk. J Clin Virol (2007) 39:1-8. doi:10.1016/j.jcv.2007.02.004
141. Moore JS, Rahemtulla F, Kent LW, Hall SD, Ikizler MR, Wright PF, et al. Oral epithelial cells are susceptible to cell-free and cell-associated HIV-1 infection in vitro. Virology (2003) 313:343-53. doi:10.1016/S0042-6822(03)00283-6
142. Wahl A, Swanson MD, Nochi T, Olesen R, Denton PW, Chateau M, et al. Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog (2012) 8:e1002732. doi:10.1371/journal.ppat.1002732.s001
143. Coovadia H, Kindra G. Breastfeeding to prevent HIV transmission in infants: balancing pros and cons. Curr Opin Infect Dis (2008) 21:11-5. doi:10.1097/QCO.0b013e3282f40689
144. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog (2010) 6:e1000852. doi:10.1371/journal.ppat.1000852
145. Henrick BM, Yao X-D, Rosenthal KL; INFANT Study Team. HIV-1 structural proteins serve as PAMPs for TLR2 heterodimers significantly increasing infection and innate immune activation. Front Immunol (2015) 6:426. doi:10.3389/fimmu.2015.00426
146. Liew FY, Xu D, Brint EK, O'Neill LAJ. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol (2005) 5:446-58. doi:10.1038/nri1630
147. LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, et al. Soluble forms of toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol (2003) 171:6680-9. doi:10.4049/jimmunol.171.12.6680
148. Dulay AT, Buhimschi CS, Zhao G, Oliver EA, Mbele A, Jing S, et al. Soluble TLR2 is present in human amniotic fluid and modulates the intraamniotic inflammatory response to infection. J Immunol (2009) 182:7244-53. doi:10.4049/jimmunol.0803517
149. Kuroishi T, Tanaka Y, Sakai A, Sugawara Y, Komine K-I, Sugawara S. Human parotid saliva contains soluble toll-like receptor (TLR) 2 and modulates TLR2-mediated interleukin-8 production by monocytic cells. Mol Immunol (2007) 44:1969-76. doi:10.1016/j.molimm.2006.09.028
150. DeVico AL, Gallo RC. Control of HIV-1 infection by soluble factors of the immune response. Nat Rev Microbiol (2004) 2:401-13. doi:10.1038/nrmicro878
151. Ledergerber B, Flepp M, Böni J, Tomasik Z, Cone RW, Lüthy R, et al. Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement. J Infect Dis (2000) 181:1280-8. doi:10.1086/315366
152. Weber JA, Baxter DH, Zhang S, Huang DY, How Huang K, Jen Lee M, et al. The microRNA spectrum in 12 body fluids. Clin Chem (2010) 56:1733-41. doi:10.1373/clinchem.2010.147405
153. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 5:522-31. doi:10.1038/nrg1379
154. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet (2012) 13:358-69. doi:10.1038/nrg3198
155. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem (2010) 79:351-79. doi:10.1146/annurev-biochem-060308-103103
156. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol (2009) 11:228-34. doi:10.1038/ncb0309-228
157. Du T, Zamore PD. microPrimer: the biogenesis and function of microRNA. Development (2005) 132:4645-52. doi:10.1242/dev.02070
158. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet (2010) 11:597-610. doi:10.1038/nrg2843
159. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 132:875-86. doi:10.1016/j.cell.2008.02.019
160. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 9:405-14. doi:10.1038/ni1575
161. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, et al. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell (2005) 120:623-34. doi:10.1016/j.cell.2004.12.038
162. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 129:1401-14. doi:10.1016/j.cell.2007.04.040
163. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 104:1604-9. doi:10.1073/pnas.0610731104
164. Zempleni J, Aguilar-Lozano A, Sadri M, Sukreet S, Manca S, Wu D, et al. Biological activities of extracellular vesicles and their cargos from bovine and human milk in humans and implications for infants. J Nutr (2017) 147:3-10. doi:10.3945/jn.116.238949
165. Alsaweed M, Lai C, Hartmann P, Geddes D, Kakulas F. Human milk cells contain numerous miRNAs that may change with milk removal and regulate multiple physiological processes. Int J Mol Sci (2016) 17:E956. doi:10.3390/ijms17060956
166. Zhou Q, Li M, Wang X, Li Q, Wang T, Zhu Q, et al. Immune-related microRNAs are abundant in breast milk exosomes. Int J Biol Sci (2012) 8:118-23. doi:10.7150/ijbs.8.118
167. Gu Y, Li M, Wang T, Liang Y, Zhong Z, Wang X, et al. Lactation-related microRNA expression profiles of porcine breast milk exosomes. PLoS One (2012) 7:e43691. doi:10.1371/journal.pone.0043691
168. Hata T, Murakami K, Nakatani H, Yamamoto Y, Matsuda T, Aoki N. Isolation of bovine milk-derived microvesicles carrying mRNAs and microRNAs. Biochem Biophys Res Commun (2010) 396:528-33. doi:10.1016/j.bbrc.2010.04.135
169. Izumi H, Kosaka N, Shimizu T, Sekine K, Ochiya T, Takase M. Bovine milk contains microRNA and messenger RNA that are stable under degradative conditions. J Dairy Sci (2012) 95:4831-41. doi:10.3168/jds.2012-5489
170. Gigli I, Maizon DO. MicroRNAs and the mammary gland: a new understanding of gene expression. Genet Mol Biol (2013) 36:465-74. doi:10.1590/S1415-47572013005000040
171. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 9:654-9. doi:10.1038/ncb1596
172. Liang H, Huang L, Cao J, Zen K, Chen X, Zhang C-Y. Regulation of mammalian gene expression by exogenous microRNAs. Wiley Interdiscip Rev RNA (2012) 3:733-42. doi:10.1002/wrna.1127
173. Ludwig A-K, Giebel B. Exosomes: small vesicles participating in intercellular communication. Int J Biochem Cell Biol (2012) 44:11-5. doi:10.1016/j.biocel.2011.10.005
174. Chen X, Liang H, Zhang J, Zen K, Zhang C-Y. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol (2012) 22:125-32. doi:10.1016/j.tcb.2011.12.001
175. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996) 183:1161-72. doi:10.1084/jem.183.3.1161
176. Kumar A. RNA interference: a multifaceted innate antiviral defense. Retrovirology (2008) 5:17. doi:10.1186/1742-4690-5-17
177. Müller S, Imler J-L. Dicing with viruses: microRNAs as antiviral factors. Immunity (2007) 27:1-3. doi:10.1016/j.immuni.2007.07.003
178. Schütz S, Sarnow P. Interaction of viruses with the mammalian RNA interference pathway. Virology (2006) 344:151-7. doi:10.1016/j.virol.2005.09.034
179. Triboulet R, Mari B, Lin Y-L, Chable-Bessia C, Bennasser Y, Lebrigand K, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science (2007) 315:1579-82. doi:10.1126/science.1136319
180. Chable-Bessia C, Meziane O, Latreille D, Robinson R, Zamborlini A, Wagschal A, et al. Suppression of HIV-1 replication by microRNA effectors. Retrovirology (2009) 6:26. doi:10.1186/1742-4690-6-26
181. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, et al. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med (2007) 13:1241-7. doi:10.1038/nm1639
182. Zhou Y, Wang X, Liu M, Hu Q, Song L, Ye L, et al. A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages. Immunology (2010) 131:40-9. doi:10.1111/j.1365-2567.2010.03270.x
183. Swaminathan G, Rossi F, Sierra L-J, Gupta A, Navas-Martín S, Martín-García J. A role for microRNA-155 modulation in the anti-HIV-1 Effects of toll-like receptor 3 stimulation in macrophages. PLoS Pathog (2012) 8:e1002937. doi:10.1371/journal.ppat.1002937
184. Swaminathan G, Navas-Martín S, Martín-García J. MicroRNAs and HIV-1 infection: antiviral activities and beyond. J Mol Biol (2014) 426:1178-97. doi:10.1016/j.jmb.2013.12.017